Tightly held registers are good at this stage of R&D and I think of the shares available on the exchange, they may see a significant uplift once some Phase 3's come back to us Q1 2023 and the company puts the finishing touches on its submissions to the FDA.
As those processes come together I imagine we'll see some key appointments announced around the sales/marketing space, or alternately, the movement and acquisitions space if that's on the cards. We'll probably know then what the plan is although flagging partnership ready, I think the tilt is towards licensing/royalties rather than carrying all costs of manufacturing, marketing and sales. Time will tell but Twiggy is no fool, I don't think he likes following, he likes to lead.
Add to My Watchlist
What is My Watchlist?
